Breast Cancer Research and Treatment

, Volume 122, Issue 3, pp 777–785

Targeting breast stem cells with the cancer preventive compounds curcumin and piperine

  • Madhuri Kakarala
  • Dean E. Brenner
  • Hasan Korkaya
  • Connie Cheng
  • Karim Tazi
  • Christophe Ginestier
  • Suling Liu
  • Gabriela Dontu
  • Max S. Wicha
Preclinical Study

Abstract

The cancer stem cell hypothesis asserts that malignancies arise in tissue stem and/or progenitor cells through the dysregulation or acquisition of self-renewal. In order to determine whether the dietary polyphenols, curcumin, and piperine are able to modulate the self-renewal of normal and malignant breast stem cells, we examined the effects of these compounds on mammosphere formation, expression of the breast stem cell marker aldehyde dehydrogenase (ALDH), and Wnt signaling. Mammosphere formation assays were performed after curcumin, piperine, and control treatment in unsorted normal breast epithelial cells and normal stem and early progenitor cells, selected by ALDH positivity. Wnt signaling was examined using a Topflash assay. Both curcumin and piperine inhibited mammosphere formation, serial passaging, and percent of ALDH+ cells by 50% at 5 μM and completely at 10 μM concentration in normal and malignant breast cells. There was no effect on cellular differentiation. Wnt signaling was inhibited by both curcumin and piperine by 50% at 5 μM and completely at 10 μM. Curcumin and piperine separately, and in combination, inhibit breast stem cell self-renewal but do not cause toxicity to differentiated cells. These compounds could be potential cancer preventive agents. Mammosphere formation assays may be a quantifiable biomarker to assess cancer preventive agent efficacy and Wnt signaling assessment can be a mechanistic biomarker for use in human clinical trials.

Keywords

Breast stem cells Cancer prevention Curcumin Piperine 

Supplementary material

10549_2009_612_MOESM1_ESM.doc (132 kb)
Supplementary material 1 (DOC 133 kb)

References

  1. 1.
    Al-Hajj M, Becker MW, Wicha M, Weissman I, Clarke MF (2004) Therapeutic implications of cancer stem cells. Curr Opin Genet Dev 14:43–47CrossRefPubMedGoogle Scholar
  2. 2.
    Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, Wicha MS (2003) In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 17:1253–1270CrossRefPubMedGoogle Scholar
  3. 3.
    Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, Asselin-Labat ML, Gyorki DE, Ward T, Partanen A, Feleppa F, Huschtscha LI, Thorne HJ, Fox SB, Yan M, French JD, Brown MA, Smyth GK, Visvader JE, Lindeman GJ (2009) Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 15:907–913CrossRefPubMedGoogle Scholar
  4. 4.
    Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1:555–567CrossRefPubMedGoogle Scholar
  5. 5.
    Liu S, Ginestier C, Charafe-Jauffret E, Foco H, Kleer CG, Merajver SD, Dontu G, Wicha MS (2008) BRCA1 regulates human mammary stem/progenitor cell fate. Proc Natl Acad Sci USA 105:1680–1685CrossRefPubMedGoogle Scholar
  6. 6.
    Cella D, Land SR, Chang CH, Day R, Costantino JP, Wolmark N, Ganz PA (2008) Symptom measurement in the Breast Cancer Prevention Trial (BCPT) (P-1): psychometric properties of a new measure of symptoms for midlife women. Breast Cancer Res Treat 109:515–526CrossRefPubMedGoogle Scholar
  7. 7.
    Gennari L, Merlotti D, Paola VD, Nuti R (2008) Raloxifene in breast cancer prevention. Expert Opin Drug Saf 7:259–270CrossRefPubMedGoogle Scholar
  8. 8.
    Clarke R, Liu MC, Bouker KB, Gu Z, Lee RY, Zhu Y, Skaar TC, Gomez B, O’Brien K, Wang Y, Hilakivi-Clarke LA (2003) Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 22:7316–7339CrossRefPubMedGoogle Scholar
  9. 9.
    Howell A (2008) The endocrine prevention of breast cancer. Best Pract Res Clin Endocrinol Metab 22:615–623CrossRefPubMedGoogle Scholar
  10. 10.
    Powles TJ (2008) Prevention of breast cancer using SERMs. Adv Exp Med Biol 630:232–236CrossRefPubMedGoogle Scholar
  11. 11.
    Lindvall C, Bu W, Williams BO, Li Y (2007) Wnt signaling, stem cells, and the cellular origin of breast cancer. Stem Cell Rev 3:157–168CrossRefPubMedGoogle Scholar
  12. 12.
    Liu S, Dontu G, Wicha MS (2005) Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res 7:86–95CrossRefPubMedGoogle Scholar
  13. 13.
    Yang W, Yan HX, Chen L, Liu Q, He YQ, Yu LX, Zhang SH, Huang DD, Tang L, Kong XN, Chen C, Liu SQ, Wu MC, Wang HY (2008) Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. Cancer Res 68:4287–4295CrossRefPubMedGoogle Scholar
  14. 14.
    Park CH, Hahm ER, Park S, Kim HK, Yang CH (2005) The inhibitory mechanism of curcumin and its derivative against beta-catenin/Tcf signaling. FEBS Lett 579:2965–2971CrossRefPubMedGoogle Scholar
  15. 15.
    Bachmeier B, Nerlich AG, Iancu CM, Cilli M, Schleicher E, Vene R, Dell’Eva R, Jochum M, Albini A, Pfeffer U (2007) The chemopreventive polyphenol Curcumin prevents hematogenous breast cancer metastases in immunodeficient mice. Cell Physiol Biochem 19:137–152CrossRefPubMedGoogle Scholar
  16. 16.
    Bachmeier BE, Mohrenz IV, Mirisola V, Schleicher E, Romeo F, Hohneke C, Jochum M, Nerlich AG, Pfeffer U (2008) Curcumin downregulates the inflammatory cytokines CXCL1 and -2 in breast cancer cells via NFkappaB. Carcinogenesis 29:779–789CrossRefPubMedGoogle Scholar
  17. 17.
    Chuang SE, Kuo ML, Hsu CH, Chen CR, Lin JK, Lai GM, Hsieh CY, Cheng AL (2000) Curcumin-containing diet inhibits diethylnitrosamine-induced murine hepatocarcinogenesis. Carcinogenesis 21:331–335CrossRefPubMedGoogle Scholar
  18. 18.
    Huang MT, Lou YR, Ma W, Newmark HL, Reuhl KR, Conney AH (1994) Inhibitory effects of dietary curcumin on forestomach, duodenal, and colon carcinogenesis in mice. Cancer Res 54:5841–5847PubMedGoogle Scholar
  19. 19.
    Huang MT, Newmark HL, Frenkel K (1997) Inhibitory effects of curcumin on tumorigenesis in mice. J Cell Biochem Suppl 27:26–34CrossRefPubMedGoogle Scholar
  20. 20.
    Bhardwaj RK, Glaeser H, Becquemont L, Klotz U, Gupta SK, Fromm MF (2002) Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 302:645–650CrossRefPubMedGoogle Scholar
  21. 21.
    Pradeep CR, Kuttan G (2004) Piperine is a potent inhibitor of nuclear factor-kappaB (NF-kappaB), c-Fos, CREB, ATF-2 and proinflammatory cytokine gene expression in B16F-10 melanoma cells. Int Immunopharmacol 4:1795–1803CrossRefPubMedGoogle Scholar
  22. 22.
    Pradeep CR, Kuttan G (2002) Effect of piperine on the inhibition of lung metastasis induced B16F-10 melanoma cells in mice. Clin Exp Metastasis 19:703–708CrossRefPubMedGoogle Scholar
  23. 23.
    Selvendiran K, Banu SM, Sakthisekaran D (2004) Protective effect of piperine on benzo(a)pyrene-induced lung carcinogenesis in Swiss albino mice. Clin Chim Acta 350:73–78CrossRefPubMedGoogle Scholar
  24. 24.
    Selvendiran K, Prince Vijeya Singh J, Sakthisekaran D (2006) In vivo effect of piperine on serum and tissue glycoprotein levels in benzo(a)pyrene induced lung carcinogenesis in Swiss albino mice. Pulm Pharmacol Ther 19:107–111CrossRefPubMedGoogle Scholar
  25. 25.
    Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS (1998) Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 64:353–356CrossRefPubMedGoogle Scholar
  26. 26.
    Huang MZ, Zhang FC, Zhang YY (2008) Influence factors on the formation of mammospheres from breast cancer stem cells. Beijing Da Xue Xue Bao 40:500–504PubMedGoogle Scholar
  27. 27.
    Korkaya H, Paulson A, Charafe-Jauffret E, Ginestier C, Brown M, Dutcher J, Clouthier SG, Wicha MS (2009) Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol 7:e1000121CrossRefPubMedGoogle Scholar
  28. 28.
    Cho RW, Wang X, Diehn M, Shedden K, Chen GY, Sherlock G, Gurney A, Lewicki J, Clarke MF (2008) Isolation and molecular characterization of cancer stem cells in MMTV-Wnt-1 murine breast tumors. Stem Cells 26:364–371CrossRefPubMedGoogle Scholar
  29. 29.
    Katoh M (2007) Networking of WNT, FGF, Notch, BMP, and Hedgehog signaling pathways during carcinogenesis. Stem Cell Rev 3:30–38CrossRefPubMedGoogle Scholar
  30. 30.
    Kwan H, Pecenka V, Tsukamoto A, Parslow TG, Guzman R, Lin TP, Muller WJ, Lee FS, Leder P, Varmus HE (1992) Transgenes expressing the Wnt-1 and int-2 proto-oncogenes cooperate during mammary carcinogenesis in doubly transgenic mice. Mol Cell Biol 12:147–154PubMedGoogle Scholar
  31. 31.
    Turashvili G, Bouchal J, Burkadze G, Kolar Z (2006) Wnt signaling pathway in mammary gland development and carcinogenesis. Pathobiology 73:213–223CrossRefPubMedGoogle Scholar
  32. 32.
    Ugolini F, Charafe-Jauffret E, Bardou VJ, Geneix J, Adelaide J, Labat-Moleur F, Penault-Llorca F, Longy M, Jacquemier J, Birnbaum D, Pebusque MJ (2001) WNT pathway and mammary carcinogenesis: loss of expression of candidate tumor suppressor gene SFRP1 in most invasive carcinomas except of the medullary type. Oncogene 20:5810–5817CrossRefPubMedGoogle Scholar
  33. 33.
    Jaiswal AS, Marlow BP, Gupta N, Narayan S (2002) Beta-catenin-mediated transactivation and cell-cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells. Oncogene 21:8414–8427CrossRefPubMedGoogle Scholar
  34. 34.
    Ryu MJ, Cho M, Song JY, Yun YS, Choi IW, Kim DE, Park BS, Oh S (2008) Natural derivatives of curcumin attenuate the Wnt/beta-catenin pathway through down-regulation of the transcriptional coactivator p300. Biochem Biophys Res Commun 377:1304–1308Google Scholar
  35. 35.
    Moen MD, Keating GM (2008) Raloxifene: a review of its use in the prevention of invasive breast cancer. Drugs 68:2059–2083CrossRefPubMedGoogle Scholar
  36. 36.
    Lao CD, Ruffin MTt, Normolle D, Heath DD, Murray SI, Bailey JM, Boggs ME, Crowell J, Rock CL, Brenner DE (2006) Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 6:10CrossRefPubMedGoogle Scholar
  37. 37.
    Aggarwal BB, Banerjee S, Bharadwaj U, Sung B, Shishodia S, Sethi G (2007) Curcumin induces the degradation of cyclin E expression through ubiquitin-dependent pathway and up-regulates cyclin-dependent kinase inhibitors p21 and p27 in multiple human tumor cell lines. Biochem Pharmacol 73:1024–1032CrossRefPubMedGoogle Scholar
  38. 38.
    Aggarwal BB, Kumar A, Bharti AC (2003) Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 23:363–398PubMedGoogle Scholar
  39. 39.
    Anuchapreeda S, Leechanachai P, Smith MM, Ambudkar SV, Limtrakul PN (2002) Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem Pharmacol 64:573–582CrossRefPubMedGoogle Scholar
  40. 40.
    Aravindan N, Madhusoodhanan R, Ahmad S, Johnson D, Herman TS (2008) Curcumin inhibits NFkappaB mediated radioprotection and modulate apoptosis related genes in human neuroblastoma cells. Cancer Biol Ther 7:569–576CrossRefPubMedGoogle Scholar
  41. 41.
    Binion DG, Otterson MF, Rafiee P (2008) Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition. Gut 57:1509–1517CrossRefPubMedGoogle Scholar
  42. 42.
    Wang Z, Zhang Y, Banerjee S, Li Y, Sarkar FH (2006) Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells. Cancer 106:2503–2513CrossRefPubMedGoogle Scholar
  43. 43.
    Prasad CP, Rath G, Mathur S, Bhatnagar D, Ralhan R (2009) Potent growth suppressive activity of curcumin in human breast cancer cells: Modulation of Wnt/beta-catenin signaling. Chem Biol Interact 181:263–271CrossRefPubMedGoogle Scholar
  44. 44.
    Ryu MJ, Cho M, Song JY, Yun YS, Choi IW, Kim DE, Park BS, Oh S (2008) Natural derivatives of curcumin attenuate the Wnt/beta-catenin pathway through down-regulation of the transcriptional coactivator p300. Biochem Biophys Res Commun 377:1304–1308CrossRefPubMedGoogle Scholar
  45. 45.
    Chearwae W, Anuchapreeda S, Nandigama K, Ambudkar SV, Limtrakul P (2004) Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II, and III purified from Turmeric powder. Biochem Pharmacol 68:2043–2052CrossRefPubMedGoogle Scholar
  46. 46.
    Limtrakul P, Chearwae W, Shukla S, Phisalphong C, Ambudkar SV (2007) Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin. Mol Cell Biochem 296:85–95CrossRefPubMedGoogle Scholar
  47. 47.
    Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB (2007) Bioavailability of curcumin: problems and promises. Mol Pharm 4:807–818CrossRefPubMedGoogle Scholar
  48. 48.
    Singh S, Khar A (2006) Biological effects of curcumin and its role in cancer chemoprevention and therapy. Anticancer Agents Med Chem 6:259–270CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2009

Authors and Affiliations

  • Madhuri Kakarala
    • 1
    • 3
  • Dean E. Brenner
    • 1
    • 2
    • 3
  • Hasan Korkaya
    • 1
  • Connie Cheng
    • 1
  • Karim Tazi
    • 1
  • Christophe Ginestier
    • 1
  • Suling Liu
    • 1
  • Gabriela Dontu
    • 1
  • Max S. Wicha
    • 1
  1. 1.Division of Hematology/Oncology, Department of Internal Medicine and Comprehensive Cancer CenterUniversity of MichiganAnn ArborUSA
  2. 2.Department of PharmacologyUniversity of MichiganAnn ArborUSA
  3. 3.VA Medical CenterAnn ArborUSA

Personalised recommendations